Tumour antigen cross-presentation: efficiency, biology and role of inhibitory B7 homologue molecules

Funded Activity Summary

It is now known that the body s immune system often attempts to attack cancers but this response is generally fairly weak. It was previously thought that one of the main reasons for this failure was that the immune system was ignorant of the presence of the cancer until too late. Our recent work over the past few years has shown that this is not the case. A process called cross-presentation seems to efficiently and continuously expose the cancer to the body s anti-cancer killer T-cells. This grant will work out exactly how efficient that process is, which cells are responsible and some aspects of how it happens. We will also study whether some recently-discovered braking molecules, which slow down immune responses and which could be 'applying the brakes' to anti-cancer responses. This could lead to new approaches to therapy eg by removing these brakes during vaccination therapy.

Funded Activity Details

Start Date: 01-01-2005

End Date: 01-01-2007

Funding Scheme: NHMRC Project Grants

Funding Amount: $469,500.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antigen presenting cells | co-stimulation | cross-presentation | immunotherapy | tumour immunology | tumours | vaccines

Related Links